Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy
Xing Cheng(Nanchang University), Hong Jin(Serimmune (United States)), JoAnn Suzich, Weijia Wang(Zhongshan People's Hospital), James A. Harper, Qi Xu(South China Agricultural University), Mark S. Galinski(Serimmune (United States)), Danielle Carroll(AstraZeneca (United Kingdom))
Cited by 81
Related Papers
Regulation of In Situ to Invasive Breast Carcinoma Transition
|Cancer Cell|2008|509
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
|Annals of the Rheumatic Diseases|2024|194
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer
|Nature Medicine|2021|115
Targeting CSC-related transcription factors by E3 ubiquitin ligases for cancer therapy
|Seminars in Cancer Biology|2022|44
SOX10 ablation severely impairs the generation of postmigratory neural crest from human pluripotent stem cells
|Cell Death and Disease|2021|34